Tag: medical product
Latanoprost Timolol eye drops recall
A Latanoprost Timolol eye drops recall has been announced by the Medicines and Healthcare Regulatory Authority (MHRA).
The company behind the eye drops, FDC Pharma, are recalling a batch due to what has been classed as an ‘out of specification result for an unknown impurity’ that was identified during testing. Medical professionals are to stop providing the eye drops to patients, and suppliers and distributors are to cease moving the eye drops as well.
The NHS has been pushing the news throughout the Service to ensure batches affected by the Latanoprost Timolol eye drops recall are not used.
Compensation for pelvic mesh problems
You can claim for personal injury compensation for pelvic mesh problems, and it’s important to claim given the severity of the issues that can arise.
We’ve spent a number of years talking about pelvic mesh problems, and we’re now at a point where the number of people suffering complications appears to be increasing, and people are far more aware of the dangers now. Only recently did the NHS finally put a widespread pause on the procedure – news we welcome – after another review into the safety and the efficacy of the devices.
With some victims left unable to walk or work for the rest of their lives, claiming compensation for personal injury and losses is incredibly important.
Pelvic mesh suits continue against Boston Scientific
Pelvic mesh suits are to continue against pharmaceutical giant Boston Scientific after a Judge denied an attempt to dismiss some 800 claims.
The major pharmaceutical companies like Boston Scientific and Johnson and Johnson seem to be trying their hardest to dismiss the thousands of claims that are currently being made against them in them around the world. The UK is somewhat behind in terms of taking full legal action for victims pursuing pelvic mesh suits, and it’s a legal action we’re involved in.
This latest failed effort to dismiss claims is another small victory in what continues to be a long, hard fight for justice.
Pelvic mesh implant complications lead to NHS halt
The increasing number of pelvic mesh implant complications has finally forced the NHS to put a widespread halt on the use of the procedure as more and more women come forward with problems over the use of transvaginal mesh and transvaginal tape.
We’ve been advising women suffering mesh implant complications since the start of 2013, and our Group Action Lawyers are involved in legal action over the use of the devices. We wholeheartedly welcome the NHS pause on the use of the implants that’s arisen from a review chaired by Baroness Julia Cumberlege.
This may prove to be another crucial step forward toward justice for the many women who have suffered catastrophic and lifelong injuries caused by mesh implant complications.
Roche Diabetes Care test strip errors leads to recall
Roche Diabetes Care test strip errors has led to a recall of a number of home-use and point-of-care glucose monitoring systems.
The Roche Diabetes Care test strip errors are for the following systems: Accu-Chek Aviva; Accu-Chek Performa; and Accu-Chek Inform II.
There is a risk of a strip error message that may lead to either falsely high or falsely low blood glucose results reported.
Calls for UK inquiry into sodium valproate epilepsy drug
There are calls for a UK inquiry into the sodium valproate epilepsy drug that has been linked to birth defects and developmental issues in children.
It’s also understood that UK health professionals were warned about the dangers of people using sodium valproate epilepsy drugs, but little seems to have been done – especially in the past – to ensure users were informed of the risks and were able to make decisions as to the use of the drug.
There are also questions over whether the drug should be classed as safe at all, and the HSE is reportedly looking at the issue. We may see a UK inquiry into the side-effects soon.
Cancer drug recall confirmed by UK regulators
A cancer drug recall has been initiated due to reports of excessive levels of an active ingredient used in the drug.
Pharmaceutical company AstraZeneca UK has initiated the recall, primarily for batch NG327, because the “level of olaparib polymorphic form L exceeds the registered specification limit”.
As well as the batch being recalled above, there are other batches that are a part of the recall as well, which is all said to be a part of a precautionary measure.
Continue Reading…